Overview
- Shares jumped about 22% intraday after the Q4 report and closed Thursday still up roughly 17% from pre‑earnings levels.
- Backlog rose 109% year over year to $15 billion as organic orders more than tripled and the book‑to‑bill ratio reached 2.9x.
- For 2025, sales grew 28% to $10.2 billion, operating profit rose 35% to $668 million, and free cash flow increased 66% to $1.8 billion.
- Management guides to 27%–29% organic net sales growth in 2026 and has indicated roughly 43% expected earnings growth, with much of 2026 capacity already sold.
- The stock trades around 39x forward earnings; options pricing points to potential gains toward $300 and analysts keep a Strong Buy view, even as the RSI reflects overbought conditions.